Acute Lymphoblastic Leukemia (ALL)

First (CR1)/ Second Remission (CR2)
- Autologous or Allogeneic
  - CCT5001
    - Phase I
    - CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Recurrent/Refractory B Cell Malignancies
      - PI: Miklos Stanford
  - BMT340
    - Phase III
    - Tacrolimus/Methotrexate vs Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in PBSCT
      - PI: Rezvani Pending
  - BMT338
    - Phase I
    - DonorGrfts DerivedFrom OrcaGraft w/GVHD Prophylaxis in MA-aloHCT in Hematologic Malignancies
      - PI: Meyer Orca Biosystems

First (CR1) or Higher Remission
- Match Related
  - BMT339
    - CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS/AL
      - PI: Lowsky Pending
  - BMT326
    - Phase III
    - Haploidentical HSCT & ATIR101 or Post-Transplant Cyclophosphamide in Hematologic Malignancy
      - PI: Johnson Kiadis Pharma

High Risk First (CR1) Remission
- Haplo
  - BMT338
    - Phase I
    - DonorGrfts DerivedFrom OrcaGraft w/GVHD Prophylaxis in MA-aloHCT in Hematologic Malignancies
      - PI: Meyer Orca Biosystems
- Allogeneic
  - BMT333
    - Phase III
    - Transplantation of NiCord vs Unmanipulated UmbilicalCordBlood in Hematological Malignancies
      - PI: Rezvani Sponsor: Gamida Cell

**KEY**
- : Pending
- : Open for Enrollment
- : Optional Path
- : Extension Study
- : Immunotherapy
- : Link
- : Trial Posting
- : Enrollment on Hold